Published in Circulation on August 01, 1992
Hypertrophic cardiomyopathy with apical aneurysm: a case of catheter and surgical therapy of sustained monomorphic ventricular tachycardia. Heart (1997) 1.14
Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2010) 1.02
Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in DeltaKPQ Scn5a murine hearts modelling human long QT 3 syndrome. Acta Physiol (Oxf) (2007) 0.99
Dispersion of cardiac action potential duration and the initiation of re-entry: a computational study. Biomed Eng Online (2005) 0.87
Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J (1994) 0.85
An activation-repolarization time metric to predict localized regions of high susceptibility to reentry. Heart Rhythm (2015) 0.83
Screening for hypertrophic cardiomyopathy. BMJ (1993) 0.78
Electrophysiological investigation of patients with hypertrophic cardiomyopathy. Evidence that slowed intraventricular conduction is associated with an increased risk of sudden death. Br Heart J (1994) 0.78
Divergence of endocardial QT interval components during programmed electrical stimulation including observations during induction of sustained ventricular tachyarrhythmias. J Interv Card Electrophysiol (1997) 0.78
Genetic investigation and counselling of families with hypertrophic cardiomyopathy. Br Heart J (1994) 0.76
Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat Rev Cardiol (2016) 0.75
Electrophysiological disturbances in heart failure. Br Heart J (1994) 0.75
Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging (2016) 0.75
Cardiopulmonary resuscitation skills of preregistration house officers. Br Med J (Clin Res Ed) (1985) 8.45
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ (1995) 6.28
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet (1999) 3.38
Insulin-stimulated translocation of glucose transport systems in the isolated rat adipose cell. Time course, reversal, insulin concentration dependency, and relationship to glucose transport activity. J Biol Chem (1981) 3.28
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J (1994) 3.13
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.97
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Insulin-stimulated translocation of glucose transporters in the isolated rat adipose cells: characterization of subcellular fractions. Biochim Biophys Acta (1983) 2.88
Cell surface labeling of glucose transporter isoform GLUT4 by bis-mannose photolabel. Correlation with stimulation of glucose transport in rat adipose cells by insulin and phorbol ester. J Biol Chem (1990) 2.84
Hormonal regulation of mammalian glucose transport. Annu Rev Biochem (1986) 2.84
Chlamydia pneumoniae and coronary heart disease. BMJ (1997) 2.73
Colour Doppler flow mapping. BMJ (1990) 2.69
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Antibiotic prophylaxis in gastrointestinal endoscopy. Gut (2009) 2.65
Left atrial appendage: structure, function, and role in thromboembolism. Heart (1999) 2.52
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (1997) 2.50
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Cost implications of the British Pacing and Electrophysiology Group's recommendations for pacing. BMJ (1992) 2.42
Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol (1991) 2.42
Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells. Evidence that exocytosis is a critical site of hormone action. J Biol Chem (1993) 2.41
Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol (1983) 2.34
Electrocardiographic changes in 1000 highly trained junior elite athletes. Br J Sports Med (1999) 2.32
Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 2.31
Relation between initial blood pressure and its fall with treatment. Lancet (1985) 2.27
Expression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 2.26
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart (2002) 2.23
Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart (2004) 2.22
The QT interval. Prog Cardiovasc Dis (2001) 2.22
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J (1985) 2.22
Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol (1994) 2.21
Where there is smoke there is fire: the Iranian system of paid donation. Am J Transplant (2013) 2.20
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J (1997) 2.16
Atrial arrhythmias. Lancet (1993) 2.13
Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol (1998) 2.03
The rhythm of the heart in active elderly subjects. Am Heart J (1980) 2.02
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf (2001) 2.02
Complete denervation of the heart in a child with congenital long QT and deafness. Am J Cardiol (1988) 2.00
Cardiac arrhythmia suppression trial and flecainide. Lancet (1989) 1.98
Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart (2007) 1.97
Stroke and alcohol consumption. N Engl J Med (1986) 1.96
Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. Lancet (1989) 1.96
Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia (1997) 1.93
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J (1981) 1.91
Components of heart rate variability--what they really mean and what we really measure. Am J Cardiol (1993) 1.91
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol (1990) 1.91
High-density substrate mapping in Brugada syndrome: combined role of conduction and repolarization heterogeneities in arrhythmogenesis. Circulation (2009) 1.83
Prevalence of granulocytic Ehrlichia infection among white-tailed deer in Wisconsin. J Clin Microbiol (1997) 1.78
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation (1999) 1.76
Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol (2001) 1.74
Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol (1992) 1.74
Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation (1998) 1.74
Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation (1990) 1.73
M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction. Am J Cardiol (1980) 1.72
Effect of intravenous propranolol on QT interval. A new method of assessment. Br Heart J (1980) 1.71
Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol (1999) 1.71
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect (1995) 1.69
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Glucose transporter proteins in brain. FASEB J (1994) 1.67
Association between residence location and likelihood of kidney transplantation in Aboriginal patients treated with dialysis in Canada. Kidney Int (2006) 1.67
Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart (2000) 1.66
Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol (1992) 1.66
Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet (1988) 1.65
Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol (2000) 1.65
Hypothermia and thermoregulatory derangements induced by valproic acid. Neurology (2000) 1.64
Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation (2001) 1.64
Classification of atrial fibrillation. Pacing Clin Electrophysiol (1997) 1.63
Mortality of Canadians treated by peritoneal dialysis in remote locations. Kidney Int (2007) 1.63
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.60
Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J (1989) 1.59
Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol (1992) 1.58
Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology (2008) 1.57
Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol (1992) 1.57